Adaptação transcultural do “EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)” para a língua portuguesa

Serrano, Érica Vieira; Valim, Valéria; Miyamoto, Samira Tatiyama; Giovelli, Raquel Altoé; Paganotti, Maurício Aquino; Cadê, Nágela Valadão

doi:10.1016/j.rbr.2013.04.003

Cited by 22 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In all these samples, the values indicate patients with low disease activity. In a study involving 62 patients with pSS for the transcultural adaptation of the ESSDAI into Brazilian Portuguese, the authors found a mean (SD) ESSDAI of 4.95 (6.73) [ 30 ]. In the present study, the ESSDAI was able to distinguish two groups of patients: 23 patients with a mean ESSDAI of 1.65 (95%CI 0.81–2.49) and 47 patients with a mean ESSDAI of 3.89 (95%CI 2.77–5.01).…”

Section: Discussionmentioning

confidence: 99%

Salivary gland ultrasonography as a predictor of clinical activity in Sjögren’s syndrome

et al. 2017

View full text Add to dashboard Cite

PurposePrimary Sjögren’s syndrome is a multisystem autoimmune disease characterized by hypofunction of salivary and lacrimal glands and possible multi-organ system manifestations. Over the past 15 years, three sets of diagnostic criteria have been proposed, but none has included salivary gland ultrasonography. However, recent studies support its role in the diagnosis and prognostic evaluation of patients with Sjögren’s syndrome. This study aimed to determine the value of salivary gland ultrasonography in the diagnosis and prognosis of Sjögren’s syndrome by relating ultrasonography severity scores to clinical and laboratory data.MethodsSeventy patients who fulfilled the 2002 American-European Consensus Group diagnostic criteria for primary Sjögren’s syndrome were selected from 84 patients receiving care in specialized outpatient clinics at our institution from November 2013 to May 2016. Their serology, European League Against Rheumatism Sjögren’s syndrome disease activity index (ESSDAI), salivary flow rate, immunoglobulin G, and salivary and serum beta-2 microglobulin levels were measured. Salivary gland ultrasonography was performed by an experienced radiologist, using scores of 1–4 to classify salivary gland impairment.ResultsSalivary gland ultrasonography scores of 1 or 2 were associated with an ESSDAI < 5. Ultrasonography scores of 3 or 4 were associated with an ESSDAI ≥5 (p = 0.064), a positive antinuclear antibody test (p = 0.006), positive anti-Ro/SSA antibodies (p = 0.003), positive anti-La/SSB antibodies (p = 0.077), positive rheumatoid factor (p = 0.034), and immunoglobulin G levels > 1600 mg/dL (p = 0.077). Salivary flow rate was lower in patients with scores 3 or 4 (p = 0.001).ConclusionThis study provides further evidence that salivary gland ultrasonography can be used not only for diagnosis but also for prognostic evaluation of primary Sjögren’s syndrome. These findings confirm what has been reported in the literature. However, further analyses involving larger matched samples are required to support this finding and include salivary gland ultrasonography as part of the diagnostic criteria for Sjögren’s syndrome.

show abstract

Section: Discussionmentioning

confidence: 99%

Salivary gland ultrasonography as a predictor of clinical activity in Sjögren’s syndrome

et al. 2017

View full text Add to dashboard Cite

show abstract

“…It has 12 domains of systemic evaluation (constitutional, lymphadenopathy, glandular, articular, cutaneous, respiratory, renal, muscular, peripheral and central nervous system, hematological and biological). The domains have different weights in the final score, 0 to 123, according to the level of activity [27,28]. Values lower than 5 are considered to indicate low disease activity; values from 5 to 13, moderate activity; and values greater than or equal to 14, high activity [29].…”

Section: Methodsmentioning

confidence: 99%

Pain and fatigue are predictors of quality of life in primary Sjögren’s syndrome

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Few studies have evaluated the relation of quality of life (QoL) with symptoms and disease activity in primary Sjögren’s syndrome (pSS). There is also scant information on the predictors of QoL in this population. The aim of this study was to assess QoL in patients with pSS and to investigate their possible predictors. Methods In a cross-sectional study, 77 patients with pSS were evaluated using the following questionnaires: Functional Assessment of Chronic Illness Therapy Fatigue Subscale (FACIT-Fatigue), EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI), EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI), Short Form-36 Health Survey (SF-36) and World Health Organization Quality of Life Assessment (WHOQOL-BREF). Seventy-seven healthy controls responded to the SF-36 and WHOQOL-BREF. The Mann-Whitney test, t-test, Pearson and Spearman correlation, and multiple regression analysis were used in the statistical analysis. Results Patients with pSS and healthy controls were matched by gender and age. The mean scores for the ESSDAI, ESSPRI and FACIT-Fatigue were 3.34 ± 4.61, 6.58 ± 2.29 and 26.17 ± 11.02, respectively. Patients had a lower employment rate (36.4% versus 62.3%, p < 0.01) and higher work disability (10.4% versus 1.3%, p < 0.01). SF-36 and WHOQOL-BREF values were lower in patients with pSS (p < 0.001), except in the WHOQOL-BREF environment domain. Pain (ESSPRI), fatigue (FACIT-Fatigue), antinuclear antibody (ANA), anti-Ro-SSA and economic class (Brazilian Economic Classification Criteria - CCEB) were independent predictors of QoL. Conclusions The main predictors of poor QoL in patients with pSS were pain and fatigue, and these symptoms had an impact regardless of disease activity, age, schooling, marital status, work disability and fibromyalgia.

show abstract

“…Baseline demographic data included AID classification criteria (18)(19)(20)(21)(22)(23), disease duration (years), AID disease activity score (26)(27)(28)(29)(30), and current use of synthetic and biological diseasemodifying anti-rheumatic drugs (DMARDs). Twenty-eight days after 17DD-YF primary vaccination, AID related symptoms, AID disease activity score, and AID-related symptoms were reassessed.…”

Section: Aid-related Clinical Recordsmentioning

confidence: 99%

Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study

et al. 2020

Self Cite

View full text Add to dashboard Cite

Yellow Fever (YF) vaccination is suggested to induce a large number of adverse events (AE) and suboptimal responses in patients with autoimmune diseases (AID); however, there have been no studies on 17DD-YF primary vaccination performance in patients with AID. This prospective non-interventional study conducted between March and July, 2017 assessed the safety and immunogenicity of planned 17DD-YF primary vaccination in patients with AID. Adult patients with AID (both sexes) were enrolled, along with healthy controls, at a single hospital (Vitória, Brazil). Included patients were referred for planned vaccination by a rheumatologist; in remission, or with low disease activity; and had low level immunosuppression or the attending physician advised interruption of immunosuppression for safety reasons. The occurrence of AE, neutralizing antibody kinetics, seropositivity rates, and 17DD-YF viremia were evaluated at various time points (day 0 (D0), D3, D4, D5, D6, D14, and D28). Individuals evaluated (n = 278), including Valim et al. Yellow Fever Vaccination-Autoimmune Diseases patients with rheumatoid arthritis (RA; 79), spondyloarthritis (SpA; 59), systemic sclerosis (8), systemic lupus erythematosus (SLE; 27), primary Sjögren's syndrome (SS; 54), and healthy controls (HC; 51). Only mild AE were reported. The frequency of local and systemic AE in patients with AID and HC did not differ significantly (8 vs. 10% and 21 vs. 32%; p = 1.00 and 0.18, respectively). Patients with AID presented late seroconversion profiles according to kinetic timelines of the plaque reduction neutralization test (PRNT). PRNT-determined virus titers (copies/mL) [181 (95% confidence interval (CI), 144-228) vs. 440 (95% CI, 291-665), p = 0.004] and seropositivity rate (78 vs. 96%, p = 0.01) were lower in patients with AID after 28 days, particularly those with SpA (73%) and SLE (73%), relative to HC. The YF viremia peak (RNAnemia) was 5-6 days after vaccination in all groups. In conclusion, consistent seroconversion rates were observed in patients with AID and our findings support that planned 17DD-YF primary vaccination is safe and immunogenic in patients with AID.

show abstract

Adaptação transcultural do “EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)” para a língua portuguesa

Abstract: The Brazilian Portuguese version of ESSDAI was shown to be adaptable, reproducible, and valid for this language.

Cited by 22 publications

References 30 publications

Salivary gland ultrasonography as a predictor of clinical activity in Sjögren’s syndrome

Salivary gland ultrasonography as a predictor of clinical activity in Sjögren’s syndrome

Pain and fatigue are predictors of quality of life in primary Sjögren’s syndrome

Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study

Contact Info

Product

Resources

About